Implementation of an Interleukin-2 National Registry: an opportunity to improve cancer outcomes - Wikidata - awgldk - TriplyDB

Implementation of an Interleukin-2 National Registry: an opportunity to improve cancer outcomes

Implementation of an Interleukin-2 National Registry: an opportunity to improve cancer outcomes

http://www.wikidata.org/entity/Q33909119

about

Characterization of PD-L1 Expression and Associated T-cell Infiltrates in Metastatic Melanoma Samples from Variable Anatomic Sites.

P2860

Q35812429-B53CEE39-7A15-4B4B-93E5-8EB6E11AE200

P2860

Implementation of an Interleukin-2 National Registry: an opportunity to improve cancer outcomes

http://www.wikidata.org/entity/Q33909119

description

2014 nî lūn-bûn

@nan

2014 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Implementation of an Interleuk ...... ity to improve cancer outcomes

@ast

Implementation of an Interleuk ...... ity to improve cancer outcomes

@en

type

label

Implementation of an Interleuk ...... ity to improve cancer outcomes

@ast

Implementation of an Interleuk ...... ity to improve cancer outcomes

@en

prefLabel

Implementation of an Interleuk ...... ity to improve cancer outcomes

@ast

Implementation of an Interleuk ...... ity to improve cancer outcomes

@en

P1433

Q33909119-D1002176-78B5-461C-BC72-72E079C5FB6D

P1476

Q33909119-ECBBFF71-C92E-44AA-8F5B-A136959537E9

P2093

Q33909119-0066F0D7-35EE-4D4B-870B-7A7E701BDDE1

Q33909119-0B90B616-4134-4949-8DF3-93B0022C242D

Q33909119-22ADDAF7-DAB6-4071-968D-0C160EF05AB3

Q33909119-26BAD0DB-4003-4A55-B7E6-E00AA8F7A582

Q33909119-DBE5892B-0BCF-48DF-A5A4-8C6FBB40B1C9

Q33909119-E60A6916-C144-4BD6-900A-666CB4A1A4EC

Q33909119-FCE15B55-2667-4A96-AD6A-CD7F5C9AA2D6

P2860

Q33909119-065CA785-C9CF-4A2B-86AA-98F5D5D1C751

Q33909119-0A30D5BA-CD5F-487B-8D7C-AF360F23BF2C

Q33909119-23D89368-510C-4B5C-B40E-F31E12847964

Q33909119-393CC7CB-02F2-4A08-9B71-4DCD6785D48F

Q33909119-4595F5A0-5811-480F-A74C-DE9AE5EC7304

Q33909119-621F5A34-74EA-4A56-A3D0-15ECAA5DE16B

Q33909119-BF946AD8-EE2F-4964-95CB-CB6622DA8CB7

Q33909119-E5AC79D7-5474-45A4-83F0-EDA7A11FDB8A

Q33909119-FD35EA24-7AD9-497A-A9C7-8E435725E1BA

P2888

Q33909119-41563BDB-E696-4E0C-A7D5-38E4B1624A5B

P304

Q33909119-3BE5F453-AE14-445F-A130-B79AEFC95AA4

P31

Q33909119-531F1708-89DB-4E5A-B711-2160C739BFB2

P356

Q33909119-6AB82962-F384-4C13-8C18-9DF2D75B43FA

P478

Q33909119-19BE430E-A915-437F-8BA2-063C59FE8C16

P577

Q33909119-C04BD39C-5D36-4FD9-8716-91DE0A160DE5

P5875

Q33909119-9F3584F3-98D6-4BA5-833B-A2EBEBDE0980

P6179

Q33909119-0251177B-BF9A-4F0A-ABB0-67D7ADE8D44F

P698

Q33909119-D636F3C0-427C-41E5-AABF-455EF6ACB55F

P932

Q33909119-62063476-2235-471C-B31A-252118496429

P356

P1433

Journal for Immunotherapy of Cancer

P1476

Implementation of an Interleuk ...... ity to improve cancer outcomes

@en

P2093

David F McDermott

http://www.w3.org/2001/XMLSchema#string

Gregory A Daniels

http://www.w3.org/2001/XMLSchema#string

Howard L Kaufman

http://www.w3.org/2001/XMLSchema#string

James N Lowder

http://www.w3.org/2001/XMLSchema#string

Michael A Morse

http://www.w3.org/2001/XMLSchema#string

Michael K Wong

http://www.w3.org/2001/XMLSchema#string

Sandra Aung

http://www.w3.org/2001/XMLSchema#string

P2860

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study.

Guidelines for the safe administration of high-dose interleukin-2.

The Use of Registries to Improve Cancer Treatment: A National Database for Patients Treated with Interleukin-2 (IL-2).

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.

Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma.

Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study.

Does matched unrelated donor transplantation have the same outcome as matched sibling transplantation in unselected patients?

A population-based overview of sequences of targeted therapy in metastatic renal cell carcinoma.

P2888

P304

20

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/2051-1426-2-20

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P577

2014-06-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

264009903

http://www.w3.org/2001/XMLSchema#string

P6179

1048620670

http://www.w3.org/2001/XMLSchema#string

P698

25031835

http://www.w3.org/2001/XMLSchema#string

P932

4100489

http://www.w3.org/2001/XMLSchema#string